Follow the Money: TRACON Pharmaceuticals, Inc.

by

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.

TRACON Pharmaceuticals, Inc. is a U.S. public pharmaceutical company that develops novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. As reported in the February 5, 2015 issue of the PharmSource Lead Sheet, TRACON raised $36 million in the closing of an initial public offering.

Corporate Highlights

  • TRACON was incorporated in Delaware in October 2004 as Lexington Pharmaceuticals. The company changed its name to TRACON Pharmaceuticals in March 2005.
  • Corporate Headquarters: San Diego, California – 5,034 square feet of office space.
  • As of December 31, 2014, TRACON had 13 employees, of whom 11 were engaged in R&D or manufacturing activities.

Sourcing Opportunities

  • TRACON plans to use the proceeds to fund preclinical and clinical development and initiate manufacturing activities required for regulatory approval of product candidates.
  • The company relies on CROs to conduct preclinical studies and clinical trials of product candidates.
  • TRACON does not own or operate facilitates for product manufacturing, storage, distribution, or testing and must rely on third parties for the manufacture of product candidates.
  • The company currently has no sales or marketing capabilities.

Business Relationships

  • In March 2014, TRACON entered into a license agreement with Santen Pharmaceutical, under which Santen obtained an exclusive, worldwide license to TRC105 for ophthalmology indications, excluding systemic treatment of ocular tumors.1

Pipeline

Product Candidate Indication Dosage Form Status Next Anticipated Step
TRC105 Age-Related Macular Degeneration Parenteral Preclinical IND expected in 2015.
TRC205 Fibrosis Parenteral Preclinical IND expected in 2016.
TRC105 Colorectal Cancer Parenteral Preclinical Phase I planned for 2015. Data expected mid to late 2016.
TRC105 Lung Cancer Parenteral Preclinical Phase I planned for 2015. Data expected early to mid 2016.
TRC102 Hematologic Malignancies Parenteral Phase I TBA
TRC102 Solid Tumors Parenteral Phase I Data expected early to mid 2015.
TRC102 Solid Tumors Oral Phase I Data expected mid to late 2015.
TRC105 Breast Cancer Parenteral Phase I Phase II planned for 2015. Data expected mid to late 2016.
TRC105 Hepatocellular Carcinoma Parenteral Phase I Phase II planned for 2015. Data expected mid to late 2016.
TRC105 Glioblastoma Parenteral Phase II Data expected late 2015.
TRC105 Hepatocellular Carcinoma Parenteral Phase II Data expected early to mid 2016.
TRC105 Soft Tissue Sarcoma Parenteral Phase II Data expected late 2015.
TRC105 Renal Cell Carcinoma Parenteral Phase IIb Data expected early to mid 2016.

 

Finances

(In $ thousands) 2013 2012
Revenues
R&D Expenditures 6,076 3,777
General & Administrative Expenditures 1,484 1,449
Total Operating Expenses 7,560 5,226
Capital Expenditures 7 10

1TRACON Pharmaceuticals, Inc. Prospectus, SEC.gov

Contact Information

TRACON Pharmaceuticals, Inc. Key Officers
8910 University Center Lane, Suite 700 Charles P. Theuer, MD, PhD, CEO & President
San Diego, CA 92122, USA Bonne Adams, SVP, Clinical Operations
Phone: 858-550-0780 Sharon Real, PhD, SVP, Product Development
Fax: 858-550-0786 Jennifer Ellis, VP, Quality Assurance
Web: www.traconpharma.com Suzy Benedict, VP, Regulatory Affairs

Read more postings by Ryan

Ryan is a Senior Research Analyst at PharmSource. He holds a BS degree in biology, with a minor in chemistry and a BA degree in Spanish, from the University of North Carolina at Chapel Hill. Prior to joining PharmSource, Ryan worked as a Research Technician in the Neuroscience Center of the UNC Chapel Hill School of Medicine, and has been a named author on research publications.

More posts by Ryan Worthen